#42 Dr Rob Coleman - Competing against Pfizer in the covid-19 vaccine race with Codagenix

What: Codagenix is a clinical-stage biotechnology company that has raised over $25 million USD in funding to develop vaccine products against influenza, the respiratory syncytial virus, dengue virus and many others. Codagenix uses a computer-based algorithm called SAVE (Synthetic Attenuated Virus Engineering) that designs viral genomes identical to wild type strains at the amino acid level, but which make less protein in human cells. These highly attenuated viruses are then used to develop vaccines for human use. Who: Rob is a trained virologist and entrepreneur, whose pivotal advances in synthetic biology have been noted in peer reviewed journals such as Science, Nature Biotechnology, and PNAS.  We talk about: Competing in the covid-19 vaccine race with Pfizer, diversifying in business, and metaphorically building the plane while you’re flying.  📝 You can also now read the accompanying "podnotes" to the episode on Substack, where key insights from every conversation will be shared for those who prefer short and snappy takeaways: founderskeepers.substack.com  Find out more:  www.founders-keepers.com  Instagram: @founderskeepers.pod  Twitter: @founders.pod  LinkedIn: https://www.linkedin.com/company/founders-keepers-podcast  Get in touch: hi@founders-keepers.com